Evidence map›Paper›PMID 39394527›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2025

Novel astatine (

Kei Yaginuma, Kazuhiro Takahashi, Seiji Hoshi, Taiki Joho, Saki Shimoyama, Naoko Hasegawa, Koki Hasegawa, Songji Zhao, Naoyuki Ukon, Syunta Makabe and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Kei YaginumaDepartment of Urology, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima, 960-1295, Japan.
Kazuhiro TakahashiAdvanced Clinical Research Center, Fukushima Medical University School of Medicine, Fukushima, Japan.
Seiji HoshiDepartment of Urology, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima, 960-1295, Japan.
Taiki JohoAdvanced Clinical Research Center, Fukushima Medical University School of Medicine, Fukushima, Japan.
Saki ShimoyamaAdvanced Clinical Research Center, Fukushima Medical University School of Medicine, Fukushima, Japan.
Naoko HasegawaAdvanced Clinical Research Center, Fukushima Medical University School of Medicine, Fukushima, Japan.
Koki HasegawaDepartment of Radiological Sciences, School of Health Sciences, Fukushima Medical University School of Medicine, Fukushima, Japan.
Songji ZhaoAdvanced Clinical Research Center, Fukushima Medical University School of Medicine, Fukushima, Japan.
Naoyuki UkonAdvanced Clinical Research Center, Fukushima Medical University School of Medicine, Fukushima, Japan.
Syunta MakabeDepartment of Urology, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima, 960-1295, Japan.
Satoru MeguroDepartment of Urology, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima, 960-1295, Japan.
Akifumi OnagiDepartment of Urology, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima, 960-1295, Japan.
Kanako MatsuokaDepartment of Urology, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima, 960-1295, Japan.
Soichiro OgawaDepartment of Urology, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima, 960-1295, Japan.
Motohide UemuraDepartment of Urology, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima, 960-1295, Japan.
Tomoki YamashitaGraduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan.
Hiroyuki SuzukiGraduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan.
Tomoya UeharaGraduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan.
Yoshiyuki KojimaDepartment of Urology, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima, 960-1295, Japan. ykojima@fmu.ac.jp.

Funding

Fukushima reconstruction budget from the Japanese government in response to the Great East Japan Earthquake Fukushima reconstruction budget from the Japanese government in response to the Great East Japan EarthquakeJapanese Urological Association Young Researcher Promotion Grant Japanese Urological Association Young Researcher Promotion GrantJSPS KAKENHI Grant JP 24K19673Kobayashi Foundation for Cancer Research Kobayashi Foundation for Cancer ResearchTakeda Science Foundation Takeda Science Foundation
6 · The paper itself

Abstract

purposeProstate-specific membrane antigen (PSMA)-targeted alpha therapy is considered a promising alternative treatment for metastatic castration-resistant prostate cancer (mCRPC). Though astatine-211 (

methodsXenograft models were prepared by subcutaneous transplantation of PSMA-positive PC-3 PIP cells into BALB/c nu/nu mice. [

results[

conclusion[

Indexed as

Antigens, SurfaceAstatineGlutamate Carboxypeptidase IIProstatic NeoplasmsSafetyAnimalsCell Line, TumorDrug StabilityHumansLigandsMaleMiceMice, Inbred BALB CPC-3 CellsRadiopharmaceuticalsTissue DistributionAntigens, SurfaceAstatineAstatine-211FOLH1 protein, humanGlutamate Carboxypeptidase IILigandsRadiopharmaceuticalsAstatine-211Metastatic castration-resistant prostate cancerNeopentyl glycol structurePreclinical evaluationProstate-specific membrane antigenTargeted alpha therapy

Identifiers

PMID39394527
PMCPMC11732874

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.